What the FDA labels say about taking them together
Gepirone and methylene blue
Gepirone's FDA label of July 14, 2026 names methylene blue in its contraindications section; the methylene blue label PlainMeds reads does not name gepirone. The gepirone label: “Starting EXXUA in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated.”
Check it at the source: the gepirone FDA label on DailyMed (effective July 14, 2026, Aytu Therapeutics, LLC); the methylene blue FDA label on DailyMed (effective May 28, 2025, American Regent, Inc.).
What does the gepirone label say about methylene blue?
Gepirone label, contraindicationsStarting EXXUA in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated.
Gepirone label, drug interactionsMonoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of EXXUA with MAOIs increases the risk of serotonin syndrome. Intervention EXXUA is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue or in patients who have taken MAOIs within the preceding 14 days. Allow at least 14 days after stopping EXXUA before starting an MAOI [see Dosage and Administration (2.8), Contraindications (4), and Warnings and Precautions (5.3) ].
Gepirone label, warnings and precautionsIf it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking EXXUA discontinue EXXUA before initiating treatment with the MAOI [see Contraindications (4) and Drug Interactions (7) ].
Source: FDA drug label (EXXUA), NDA021164 (Fabre Kramer), as published by Aytu Therapeutics, LLC, effective July 14, 2026 (SPL set 0c78edd8-6acb-433c-9d34-2527da8d64e1), via openFDA; the full label on DailyMed
What does the methylene blue label say about gepirone?
Methylene blue's label (effective May 28, 2025) does not name gepirone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (PROVAYBLUE), NDA204630 (Provepharm Sas), as published by American Regent, Inc., effective May 28, 2025 (SPL set 4f6848e5-35ed-4046-b13c-3032b5ba3232), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Gepirone | Methylene blue | |
|---|---|---|
| Labeled for | Depression | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $57.47 per tablet 18.2 mg tablet (titratn) | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once